Our Focus
Revolutionary advances in AI are speeding early drug discovery. However, the FDA-regulated phases of drug development represent ~70% of the cost and majority of the time. To realize the biggest impacts, this space is where more innovation is needed.
Translational Cures is a unique regulatory science drug development company dedicated to leveraging the power of translational science, human expertise, and artificial intelligence to significantly shorten the drug development timeline—potentially cutting it by years.
Our primary focus is developing drugs where it was previously not possible (such as for rare diseases and emergency care) and speeding development at lower cost for common diseases.
Rare Diseases
For use cases when conventional large clinical trials are not possible
Challenge
Rare disease drug development is challenging because of the small number of patients, which makes it infeasible to conduct large clinical trials
Solution
Translational Cures uses innovative approaches, like modeling and simulation and in vitro clinical trials, to develop drugs where traditional drug development is not possible.
Emergency Care
For use cases where conventional clinical trials are too risky
Challenge
Testing new therapies for emergency care via conventional trials puts subjects at too great a risk. Often, these interventions are most needed for difficult-to-reach populations.
Solution
Translational Cures has deep expertise in evaluating emergency care therapies and understands the possibilities of using non-conventional clinical trials to advance drug development programs forward in this area.
Common Diseases
For all drug programs that want to accelerate product approval
Challenge
Although conventional trials may be viable, the associated costs and timelines of the drug development process can often be prohibitively high
Solution
Translational Cures’ innovative approaches can be applied across all disease and therapeutic areas, accelerating the path to bringing more cures to market—faster.